This is the authors' abstract. We don't add key points for this paper.
A September 2026 study used carbon-13 isotope tracing and high-resolution mass spectrometry to follow aflatoxin B1 and fumonisins through pilot-scale gluten-free pasta manufacture. It found no confirmed transformation products within the method’s detection scope, challenging the assumption that ordinary thermal processing reliably destroys these contaminants. The broader problem is not simply toxin persistence since apparent reductions in measured parent compounds can reflect dilution, physical redistribution, incomplete extraction, chemical transformation or analytical blind spots, none of which alone establishes reduced toxicological risk. This article proposes a process-fate verification framework separating legal compliance, molecular transformation, exposure and biological hazard. It compares the EU’s contaminant limits and prohibition on deliberate chemical detoxification of food with its distinct authorised assessment pathway for feed, the diverging Great Britain framework and the United States’ guidance-based approach to fumonisins. It also identifies research priorities for modified mycotoxins, emerging plant-protein ingredients and evidence-based industrial validation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Jose Manuel López (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: